RedChip

Aridis (Nasdaq: ARDS) is revolutionizing how we treat infectious diseases through its unique technology platforms, which can quickly detect human-derived mAbs to treat infectious diseases. The Company's transformative approach utilizes a patient's own immune system to identify mAbs capable of fighting infections and underpins multiple late-stage programs. In January, Aridis announced positive top-line data from the first of two Phase 3 studies of its lead candidate, AR-301, for the treatment of VAP caused by Gram-positive bacteria Staphylococcus aureus (S. aureus). In March, Aridis announced positive top-line data from its Phase 2a trial in cystic fibrosis, meeting primary and second endpoints for the study. Aridis received agreement from the FDA for a single confirmatory Phase 3 study of AR-301 in May 2023 and is discussing results of its CF study with the FDA and the EMA to plan the definitive next steps. The Cystic Fibrosis Foundation is the largest shareholder of Aridis and has invested $12.5 million into the Company to date. Learn more at AridisPharmainfo.com. 0:00 Start 0:20 Company Overview 1:40 FDA Agreement 2:45 Positive Results 5:03 Management 6:15 Value Proposition

This week's episode of the RedChip Money Report includes interviews with senior executives of Soligenix and Unicycive. Visit RedChip.com to learn more.

Alarum Technologies (Nasdaq, TASE: ALAR) is a global provider of internet access solutions. The Company operates in two distinct segments: solutions for enterprises and solutions for consumers. The solutions by NetNut, Alarum’s Enterprise Internet Access arm, are based on the world’s fastest and most advanced and secured hybrid proxy network, enabling customers to collect data anonymously at any scale from any public sources over the web. NetNut’s network comprises both exit points based on proprietary reflection technology and hundreds of servers located at ISP partners around the world. The infrastructure is optimally designed to guarantee privacy, quality, stability, and the speed of the service. Alarum’s Consumer Internet Access arm offers privacy and cybersecurity solutions to end users. These solutions are designed to allow users to take charge of their online privacy with a powerful, secured, and encrypted connection. The solutions are designed for basic and advanced use cases, ensuring complete protection of personal and digital information. The Company’s previously developed cybersecurity solutions for enterprises are offered by an information security provider, as a solution or cloud service. Visit [ALARinfo.com](http://ALARinfo.com) to learn more.

This week’s episode of the RedChip Money Report includes interviews with senior executives from Rail Vision (NASDAQ: RVSN) and Aridis Pharma (NASDAQ: ARDS). Visit RedChip.com to learn more.

This week’s episode of the RedChip Money Report includes interviews with senior executives from Graphex (NYSE American: GRFX) and ASP Isotopes (NASDAQ: SNGX). Visit RedChip.com to learn more.

ASP Isotopes (NASDAQ: ASPI) is an isotope enrichment company utilizing technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses. Many of these elements are unsuitable for enrichment using traditional methods such as centrifuges. The company's first commercial product will be Molybdenum 100, which has the potential to replace Molybdenum 99, a commonly used product in the diagnostic imaging market. Visit ASPIinfo.com to learn more.

ASP Isotopes (NASDAQ: ASPI) is an isotope enrichment company utilizing technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses. Many of these elements are unsuitable for enrichment using traditional methods such as centrifuges. The Company is initially focused on commercializing Molybdenum 100, which has the potential to replace Molybdenum 99, a commonly used product in the diagnostic imaging market, and Carbon-14, the most frequently used radiolabel for drug discovery, drug metabolism, and pharmacokinetics. Visit ASPIinfo.com to learn more.

Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company specializing in developing and commercializing products to treat rare diseases with unmet medical needs. The Company's primary focus is on its Specialized BioTherapeutics business segment, which is responsible for the development of HyBryte™, a novel photodynamic therapy that uses safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). The Company has successfully completed a Phase 3 study for HyBryte™ and is now negotiating a confirmatory Phase 3 pivotal study design with the US Food & Drug Administration, while also evaluating/pursuing potential HyBryte™ marketing approval ex-U.S. with the successfully completed Phase 3 study. Visit SNGXinfo.com to learn more.

A biotech dedicated to developing treatments for unmet medical needs, Unicycive Therapeutics (NASDAQ: UNCY) is currently advancing two programs focused on kidney disease and intends to expand its pipeline to target additional indications within and outside kidney disease. Unicycive is preparing to commercialize and launch its lead therapy, Renazorb, for treatment of hyperphosphatemia in patients with chronic kidney disease and is continuing development of UNI 494 for treatment of acute kidney injury. Visit UNCYinfo.com to learn more.

This week’s episode of the RedChip Money Report includes interviews with senior executives from Unicycive Therapeutics (NASDAQ: UNCY) and Alarum (NASDAQ: ALAR). Visit RedChip.com to learn more.

Aridis Pharmaceuticals (NASDAQ: ARDS) is advancing multiple clinical stage monoclonal antibodies (mAbs) targeting bacteria that cause life-threatening infections such as ventilator associated pneumonia (VAP) and hospital acquired pneumonia (HAP), in addition to preclinical stage antiviral mAbs. The use of mAbs as anti-infective treatments represents an innovative therapeutic approach that harnesses the human immune system to fight infections and is designed to overcome the deficiencies associated with the current standard of care which is broad spectrum antibiotics. Such deficiencies include, but are not limited to, increasing drug resistance, short duration of efficacy, disruption of the normal flora of the human microbiome and lack of differentiation among current treatments. The mAb portfolio is complemented by a non-antibiotic novel mechanism small molecule anti-infective candidate being developed to treat lung infections in cystic fibrosis patients. Visit AridisPharmaInfo.com to learn more.

Rail Vision (NASDAQ: RVSN) is the leading provider of obstacle detection and classification systems in the railway industry. With the Company’s unique cognitive sensor fusion technology, based on advanced electro-optic sensors, artificial intelligence and deep learning, Rail Vision systems detect objects on and along the tracks from a distance of up to two kilometers – in real time – as well as in all weather and light conditions. Tailormade to meet every customer’s specific needs, the systems are available for Main Lines and Shunting Yards, as well as Light Rail Vehicles (LRVs) operating in urban environments. In addition, Rail Vision offers a range of optional complementary features based on collected and analyzed data: Image-based Navigation, GIS Mapping and Predictive Maintenance. Visit RVSNinfo.com to learn more.

Our 30-minute TV show, produced in our state-of-the-art studio at our headquarters in Orlando, FL, airs in more than 100 million homes on national financial channels, including Bloomberg as a paid program. The RedChip Money Report™ features interviews with public and private companies with market caps ranging from $20 million to $2 billion. Wall Street analysts, portfolio managers, and other industry experts regularly appear on the show. Visit RedChip.com to learn more.

RedChip Investor Group Call with Soligenix (NASDAQ: SNGX) Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (SGX301 or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With a successful Phase 3 study completed, regulatory approval is being sought and commercialization activities for this product candidate are being advanced initially in the U.S.

This week’s episode of the RedChip Money Report includes interviews with senior executives from Graphex (NYSE American: GRFX) and Soligenix (NASDAQ: SNGX). Visit RedChip.com to learn more.

Everything Blockchain (OTC: EBZT) builds platforms of trust for the modern enterprise and is on a mission to ensure every organization has access to the tools and platforms that enable them to manage, store, and protect data without the cost and complexity that holds them back today. The Company’s patented advances in engineering deliver the essential elements needed for real-world business use: speed, security, and efficiency. Everything Blockchain’s current business lines include: EB Advise, Build DB and EB Control. Visit EBZTinfo.com to learn more.

A biotech dedicated to developing treatments for unmet medical needs, Unicycive Therapeutics (NASDAQ: UNCY) is currently advancing two programs focused on kidney disease and intends to expand its pipeline to target additional indications within and outside kidney disease. Unicycive is preparing to commercialize and launch its lead therapy, Renazorb, for treatment of hyperphosphatemia in patients with chronic kidney disease and is continuing development of UNI 494 for treatment of acute kidney injury. Visit UNCYinfo.com to learn more.

Greenwich LifeSciences (NASDAQ: GLSI) is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu (human epidermal growth factor receptor 2) protein, a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or “over-expressor”) levels. Visit GLSIinfo.com to learn more.

Alarum Technologies Ltd. (NASDAQ: ALAR) is a global provider of internet access solutions for enterprises and solutions for consumers. The Company's Enterprise Internet Access segment operates under the NetNut brand and is based on the world’s fastest and most advanced and secure hybrid proxy network, enabling customers to collect data anonymously at any scale from any public sources over the web. The infrastructure is optimally designed to guarantee the privacy, quality, stability, and the speed of the service. Alarum's Consumer Internet Access segment, operating under the CyberKick brand, offers privacy and cybersecurity solutions to end users. These solutions are designed to allow users to take charge of their online privacy with a powerful, secured, and encrypted connection. The solutions are designed for basic and advanced use cases, ensuring complete protection of personal and digital information. Visit ALARinfo.com to learn more.

American Resources Corp. (NASDAQ: AREC) is building one of the most unique growth platforms to strategically align old-world, legacy assets with a more modern economy. The Company is focused on extracting and processing metallurgical carbon, an essential ingredient used in steelmaking, critical and rare earth minerals for the electrification market, and reprocessed metal to be recycled. American Resources has a growing portfolio of operations located in Kentucky, Indiana, and West Virginia where premium quality metallurgical carbon and rare earth mineral deposits are concentrated. Visit ARECinfo.com to learn more.

Graphex Group (NYSE American: GRFX) is a global leader in the mid-stream deep processing of natural spherical graphite and graphene-related products, key components of the Lithium-ion (Li-ion) batteries used in Electric Vehicles (EVs), renewable energy storage systems, and other use cases. With over a decade of production experience operating at commercial-scale volumes and quality, Graphex is currently producing over 10,000 metric tons of specialized spherical graphite anode materially annually and holds patents in areas including products, production methods, machinery design, and environmental protection. With a strategy to expand its operations to support energy transition and electrification efforts worldwide, Graphex is uniquely positioned at a foundational level to grow with the industry. Visit GRFXinfo.com to learn more.

Genetic Technologies (NASDAQ: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GENE offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. Visit GeneticTechInfo.com to learn more.

Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company specializing in developing and commercializing products to treat rare diseases with unmet medical needs. The Company's primary focus is on its Specialized BioTherapeutics business segment, which is responsible for the development of HyBryte™, a novel photodynamic therapy that uses safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). The Company has successfully completed a Phase 3 study for HyBryte™ and is now negotiating a confirmatory Phase 3 pivotal study design with the US Food & Drug Administration, while also evaluating/pursuing potential HyBryte™ marketing approval ex-U.S. with the successfully completed Phase 3 study. Visit SNGXinfo.com to learn more.

This week’s episode of the RedChip Money Report includes interviews with senior executives from QYOU Media (OTCQB: QYOUF) and Graphex (NYSE American: GRFX). Visit RedChip.com to learn more.

QYOU Media (OTCQB: QYOUF) has added to the depth and breadth of its products and capabilities throughout 2022. With five active channels now in India and the addition of ChtrSocial in India and Q Studios in the US, QYOU Media is rapidly advancing its push towards driving increased audience size and strong revenue growth in 2023 and beyond. Building on a solid foundation with accelerating momentum among major advertisers, QYOU Media is ideally positioned for long-term success. Visit QYOUFinfo.com to learn more.